Instituto Di Ricerche Di Biologia Molecolare P. Angeletti

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.r.l.

Laura Llauger Bufi

Philip Jones

Giovanna Pescatore

Olaf Kinzel

Rita Scarpelli

Raffaele Ingenito

Federica Ferrigno

Michael Rowley

Jesus Maria Ontoria Ontoria

Ester Muraglia

Carsten Schultz-Fademrecht

Barbara Attenni

Caterina Torrisi

Jesus Maria Ontoria

Carsten Schultz

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.

Tricyclic derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP)

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.

Pyridinone and pyridazinone derivatives as inhibitors of poly (ADP-ribose) polymerase (PARP)

The present invention relates to compounds of formula I: or pharmaceutically acceptable salts or tautomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.

Heterocycle derivatives as histone deacetylase (HDAC) inhibitors

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment. 

[object Object]

Growing community of inventors

Pomezia, Italy

Laura Llauger Bufi